# Open-Label Extension Study of Setmelanotide

> **NCT06596135** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Rhythm Pharmaceuticals, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Obesity Associated With Defects in Leptin-melanocortin Pathway

## Interventions

- **DRUG:** Setmelanotide

## Key facts

- **NCT ID:** NCT06596135
- **Lead sponsor:** Rhythm Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-10-21
- **Primary completion:** 2027-10-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06596135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06596135, "Open-Label Extension Study of Setmelanotide". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06596135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*